Compounds > 3,3'-diindolylmethane
Page last updated: 2024-10-26

3,3'-diindolylmethane and Endometrial Neoplasms

3,3'-diindolylmethane has been researched along with Endometrial Neoplasms in 2 studies

3,3'-diindolylmethane: anti-inflammatory from edible cruciferous vegetables; a cytochrome P-450 antagonist

Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Leong, H2
Riby, JE1
Firestone, GL2
Bjeldanes, LF2

Other Studies

2 other studies available for 3,3'-diindolylmethane and Endometrial Neoplasms

ArticleYear
Potent ligand-independent estrogen receptor activation by 3,3'-diindolylmethane is mediated by cross talk between the protein kinase A and mitogen-activated protein kinase signaling pathways.
    Molecular endocrinology (Baltimore, Md.), 2004, Volume: 18, Issue:2

    Topics: Adenocarcinoma; Anticarcinogenic Agents; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dep

2004
Cytostatic effects of 3,3'-diindolylmethane in human endometrial cancer cells result from an estrogen receptor-mediated increase in transforming growth factor-alpha expression.
    Carcinogenesis, 2001, Volume: 22, Issue:11

    Topics: Adenocarcinoma; Alkaline Phosphatase; Anticarcinogenic Agents; Blotting, Northern; Blotting, Western

2001